ARCTURUS THERAPEUTICS HOLDINGS INC. Financials Arcturus Therapeutics Holdings Inc.
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.55 USD | +1.45% |
|
+2.19% | -15.79% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 164.5 | 1,122 | 975.6 | 450.4 | 842.6 | 714.6 | - | - |
| Enterprise Value (EV) 1 | 164.5 | 672.7 | 668.2 | 149.4 | 576.5 | 350.7 | 714.6 | 714.6 |
| P/E ratio | -5.06 x | -12.2 x | -4.78 x | 48.5 x | -31.5 x | -10.2 x | -154 x | 4.63 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.92 x | 118 x | 78.9 x | 2.19 x | 4.96 x | 4.86 x | 2.96 x | 1.42 x |
| EV / Revenue | 7.92 x | 70.5 x | 54.1 x | 0.73 x | 3.39 x | 2.39 x | 2.96 x | 1.42 x |
| EV / EBITDA | - | - | -3.31 x | 10.9 x | -7.99 x | -9.69 x | -11.8 x | - |
| EV / FCF | - | -15,081,355 x | -2,827,861 x | - | - | - | -5,231,751 x | -8,827,013 x |
| FCF Yield | - | -0% | -0% | - | - | - | -0% | -0% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 15,138 | 25,858 | 26,361 | 26,555 | 26,723 | 26,915 | - | - |
| Reference price 2 | 10.87 | 43.38 | 37.01 | 16.96 | 31.53 | 26.55 | 26.55 | 26.55 |
| Announcement Date | 3/11/20 | 3/1/21 | 2/28/22 | 3/28/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20.79 | 9.539 | 12.36 | 206 | 169.9 | 147 | 241.1 | 503.3 |
| EBITDA 1 | - | - | -201.7 | 13.7 | -72.11 | -36.2 | -60.49 | - |
| EBIT 1 | -25.51 | -71.52 | -202.9 | 12.18 | -75.07 | -78.56 | -5.063 | 231 |
| Operating Margin | -122.72% | -749.81% | -1,641.33% | 5.91% | -44.18% | -53.43% | -2.1% | 45.89% |
| Earnings before Tax (EBT) 1 | -25.99 | -72.15 | -203.7 | 10.64 | -24.76 | -67.88 | 14.62 | 234.9 |
| Net income 1 | -25.99 | -72.15 | -203.7 | 9.349 | -26.59 | -68.28 | 3.499 | 157.6 |
| Net margin | -125.02% | -756.35% | -1,647.98% | 4.54% | -15.65% | -46.44% | 1.45% | 31.32% |
| EPS 2 | -2.150 | -3.550 | -7.740 | 0.3500 | -1.000 | -2.609 | -0.1729 | 5.740 |
| Free Cash Flow | - | -44.6 | -236.3 | - | - | - | -136.6 | -80.96 |
| FCF margin | - | -467.59% | -1,911.95% | - | - | - | -56.66% | -16.08% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/1/21 | 2/28/22 | 3/28/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.437 | 5.794 | 5.244 | 27.09 | 13.37 | 160.3 | 80.28 | 10.52 | 45.14 | 33.99 | 17.67 | 26.14 | 48.73 | 57.05 | 74.66 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -14.32 | -43.77 | -18.67 | -19.81 | - | - |
| EBIT 1 | -53.82 | -37.64 | -50.38 | -22.09 | -36.81 | 121.5 | 14.76 | -55.37 | -19.31 | -15.14 | -37.8 | -27.85 | -10.88 | -3.89 | 8.241 |
| Operating Margin | -2,208.49% | -649.72% | -960.7% | -81.53% | -275.32% | 75.77% | 18.38% | -526.42% | -42.79% | -44.54% | -213.9% | -106.55% | -22.32% | -6.82% | 11.04% |
| Earnings before Tax (EBT) 1 | -54.08 | -38.66 | -51.17 | -21.56 | -35.27 | 118.6 | 50.86 | -51.97 | -15.33 | -8.311 | -34.65 | -26.79 | -7.33 | -1.586 | 8.091 |
| Net income 1 | -54.08 | -38.66 | -51.17 | -21.56 | -35.27 | 117.3 | 50.75 | -52.55 | -16.22 | -8.573 | -32.83 | -27.07 | -8.073 | -2.73 | 1.075 |
| Net margin | -2,219.29% | -667.31% | -975.76% | -79.59% | -263.79% | 73.21% | 63.22% | -499.57% | -35.94% | -25.22% | -185.75% | -103.54% | -16.57% | -4.79% | 1.44% |
| EPS 2 | -2.050 | -1.470 | -1.940 | -0.8200 | -1.330 | 4.330 | 1.870 | -1.980 | -0.6100 | -0.3200 | -1.228 | -0.9608 | -0.2189 | 0.0250 | 0.005000 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/28/22 | 5/9/22 | 8/9/22 | 11/9/22 | 3/28/23 | 5/9/23 | 8/7/23 | 11/14/23 | 3/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 449 | 307 | 301 | 266 | 364 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -44.6 | -236 | - | - | - | -137 | -81 |
| ROE (net income / shareholders' equity) | - | - | -65.2% | 3.75% | -9.64% | -47.7% | -68% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.82 | 1.74 | - | 7.73 | 2.9 | 8 | 6.61 | 7.17 |
| Capex / Sales | 3.93% | 18.26% | - | 3.75% | 1.71% | 5.44% | 2.74% | 1.42% |
| Announcement Date | 3/11/20 | 3/1/21 | 2/28/22 | 3/28/23 | 3/7/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
26.55
USD
Average target price
67.89
USD
Spread / Average Target
+155.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.79% | 715M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ARCT Stock
- Financials Arcturus Therapeutics Holdings Inc.
